文献速递其他结缔组织病

静脉注射免疫球蛋白治疗抗黑色素瘤分化相关基因5阳性皮肌炎的间质性肺病

Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该回顾性研究纳入2018年9月至2020年6月郑州大学第一附属医院新发抗MDA5阳性皮肌炎相关快速进展型间质性肺病患者,比较IVIG组(n=31)与非IVIG组(n=17)的预后。IVIG组6个月死亡率显著低于非IVIG组(22.6% vs 52.9%,P=0.033),3个月缓解率更高(71.0% vs 41.2%,P=0.044)。作者认为IVIG辅助治疗是此类患者非常有效的一线治疗。

要点

  • IVIG组6个月死亡率22.6%,非IVIG组52.9%(P=0.033)。
  • IVIG组3个月缓解率71.0%,非IVIG组41.2%(P=0.044)。
  • 前3个月抗MDA5抗体滴度、铁蛋白水平和GGO评分逐步下降。

核心结论

  • 作者认为IVIG辅助治疗是MDA5-RPILD患者非常有效的一线治疗。
  • 作者认为IVIG可能通过降低铁蛋白浓度、抗MDA5滴度和GGO评分来提高生存率和缓解率。

研究设计与样本

  • 回顾性研究,纳入2018年9月至2020年6月郑州大学第一附属医院新发MDA5-RPILD患者,随访6个月。
  • 患者分为IVIG组(n=31)和非IVIG组(n=17)。
  • 主要结局指标为两组3个月和6个月死亡率的差异。

主要发现

  • IVIG组6个月死亡率显著低于非IVIG组(22.6% vs 52.9%;P=0.033)。
  • IVIG组3个月缓解率显著高于非IVIG组(71.0% vs 41.2%;P=0.044)。
  • 前3个月抗MDA5自身抗体滴度、血清铁蛋白水平和磨玻璃影(GGO)评分逐步下降。

临床怎么用

  • 作者认为IVIG辅助治疗是MDA5-RPILD患者非常有效的一线治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Rapidly progressive interstitial lung disease (RP-ILD) in DM patients positive for anti-melanoma differentiation-associated gene 5 (anti-MDA5) autoantibody (MDA5-DM) often have a poor prognosis, frequently fatal. As there is a scarcity of data regarding the effect of intravenous immunoglobulin (IVIG) on RP-ILD in MDA5-DM patients (MDA5-RPILD), we conducted this study to determine the efficacy of a IVIG add-on initial treatment. METHODS: Patients with newly-onset MDA5-RPILD from September 2018 to June 2020 were retrospectively reviewed for 6 months in the First Affiliated Hospital of Zhengzhou University. They were divided into two groups: IVIG and non-IVIG groups. The major measurement of treatment outcome was the difference in the mortality in 3-month and 6-month between two group patients. Other relevant indicators were also recorded, including the incidence of infection, the dosages of GCs, the remission rate and the variables in laboratory data. RESULTS: The IVIG group (n = 31) showed significantly lower 6-month mortality rate than the non-IVIG group (n = 17) (22.6% vs 52.9%; P =0.033). The IVIG group patients had a higher remission rate at 3 months (71.0% vs 41.2%; P =0.044). Gradual reduction was observed in the first 3 months with regard to the titre of anti-MDA5 autoantibody, the serum level of ferritin and the ground glass opacification GGO scores. CONCLUSION: IVIG adjunct therapy is a very effective first-line treatment for patients with MDA5-RPILD. IVIG may increase the survival and remission rate by lowering ferritin concentration, anti-MDA5 titre and GGO score.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Wang LM, Yang QH, Zhang L, et al. Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Rheumatology (Oxford). 2022. PMID: 34940809. doi:10.1093/rheumatology/keab928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。